Search Results for: BeiGene
Editors' Picks weekly highlights
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
Partnerships Oncology
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Editors' Picks ADCsDrug Approval
GeneOnline’s Weekly News Highlights: July 10-14
2023-07-17
Special Cell TherapyBeiGene
Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All
2023-07-04
Licensing Bispecific Antibody
Jazz Opts Into License Zymeworks’ Solid Tumor Med With $325 Million Payment
2022-12-21
Partnerships CAR T-cell Therapy
Kite And Arcellx Join Forces for Developing Cell Therapy targeting Multiple Myeloma
2022-12-12
Interviews BeiGene
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
R&D Opdivo
Taiwan Greenlights BMS, Ono’s Opdivo For Frontline Esophageal Cancer
2022-07-20
Licensing China
Amgen Out-Licenses Two Therapies to Fosun Pharma to Expand Presence in China
2022-06-28
PRNewswire
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
2022-06-26
China BeiGene
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
Regulatory BeiGene
EMA Begins Review of BeiGene, Novartis’s PD-1 Antibody for Esophageal and Lung Cancer
2022-04-13
Special China
Biotech Showcase 2022: The China Factor
2022-01-24
COVID-19 COVID-19
AstraZeneca’s Covid-19 Booster and Antibody Cocktail Retains Neutralizing Ability against Omicron
2021-12-27
Licensing Immuno-oncologyNovartis
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
1 2 3 4
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top